Impact of glucocorticoid therapy on short- and long-term mortality in immunocompromised patients with community-acquired pneumonia in the ICU: a retrospective cohort study
Abstract
The number of immunocompromised patients with community-acquired pneumonia (CAP) admitted to intensive care unit (ICU) is rising, accompanied by high mortality. Although glucocorticoid (GC) therapy is recommended for severe CAP by Society of Critical Care Medicine (SCCM) in 2024, its efficacy in immunocompromised patients remains uncertain. This study aimed to evaluate the impact of GC therapy on mortality in immunocompromised patients with CAP in the ICU. A retrospective cohort study was conducted using the MIMIC-IV 3.1 database. Primary outcomes was twenty-eight days (28-d) mortality. Secondary outcomes included six months (6-m) and twelve months (12-m) mortality, in-hospital mortality, ICU mortality, hospital and ICU length of stay, and 28-d ventilator-free days. Propensity score matching (PSM) was applied to minimize selection bias. Cox proportional hazards models were used to assess the association between GC therapy and mortality, also including analyses of timing, duration, and average daily dose of GC administration. Sensitivity analysis was performed using E-values. A total of 1770 patients were included, with 593 receiving antibiotics plus GC therapy. After PSM, 521 patients were included in both the GC and non-GC treatment groups. GC therapy was associated with increased 28-d mortality (GC vs non-GC, after PSM: 29% vs 23%, HR = 1.373, p 48 hours after ICU admission, treatment duration > 7 days, and low-dose GC (≤0.5 mg/kg/d) were also linked to higher 28-d…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,770 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.